Cureus · 2023 · 16 citations · 6 references
PharmacyPharmacologyPharmacotherapyDiabetologyImmunotherapyInflammationDiabetes ManagementDiabetes MellitusDiabetes PharmacotherapyGlucagon-like Peptide-1 Receptor AgonistsIncretin-based TherapiesPancreatic DiseasesGlucagon-like Peptide 1 Receptor AgonismGlucagon-like PeptidesGlucose-stimulated Insulin SecretionInsulin Secretion EnhancementPancreatic InjuryPancreatitis RiskSmall-molecule Glp-1 Receptor AgonistsWeight Loss Drug
The Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6) trial showed that semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), is effective in managing type 2 diabetes by stimulating insulin secretion and promoting weight loss. Though recent evidence suggests no increased risk of acute pancreatitis (AP) with subcutaneous semaglutide use, some studies report an increase in pancreatic inflammation with GLP-1 RAs. We present a case of AP in a patient recently started on subcutaneous semaglutide for type 2 diabetes. As GLP-1 RA use increases, clinicians should be aware of their potential to cause acute pancreatitis.
6
Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies
Michael Elashoff, Aleksey V. Matveyenko, Belinda Gier et al. · Gastroenterology · 2011 · 931 citations · Full text
Medicine, Endocrinology, Oncology +14
Lulu Liu, Jia Chen, Lei Wang et al. · Frontiers in Endocrinology · 2022 · 225 citations · Full text